CD8A and neoplasm: Specifically, Mosunetuzumab exerts its action at low concentrations through the activation of CD69+ CD8+ T cells, with a maximum tumor depletion after 24 h of administration, while the decrease in its cytotoxic activity usually occurs after three days [81].